Mrk stock forecast the latest MRK stock forecast shows

The latest MRK stock forecast shows steady upside momentum, with analysts revising 12-month targets to $130–$135 amid robust Q1 earnings and strong pharmaceutical pipeline growth, particularly in oncology. Trading volume remains above its 30-day average, suggesting institutional accumulation. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Merck. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Despite its steeper valuation, AbbVie is a clear-cut winner due to rising estimates, stock price appreciation, a solid pipeline and the prospect of further growth in sales and profits in the second half of 2025. The MRK stock forecast holds positive bias as hedge funds increase positions, evident from 13F filings showing a net uptick in holdings over the last reporting period.